Trials / Unknown
UnknownNCT00470808
The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- HaEmek Medical Center, Israel · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Diabetes is a highly atherogenic disease. Pomegranate juice has impressive antioxidant properties. It has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques in hypercholestrolemic and diabetic patients.Furthermore it has been proven to potentiate the biologic activity of the enzyme paraoxonase 1 which is very important in preventing atherosclerosis. The study will try to prove that a polyphenolic extract from pomegranate (POMx) has the same desired effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | POMx |
Timeline
- Start date
- 2007-05-01
- Completion
- 2007-08-01
- First posted
- 2007-05-08
- Last updated
- 2007-05-08
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00470808. Inclusion in this directory is not an endorsement.